Multiple Sclerosis Clinical Trials

109 studies are recruiting for multiple sclerosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

   The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or …

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Johns Hopkins University, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT07389590 on ClinicalTrials.gov

2. ECoG BMI for Motor and Speech Control

   Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.

   Stage

   Not phased

   Ages

   21 and older

   Site

   University of California San Francisco, San Francisco, California

   Run by

   Karunesh Ganguly

   See if you can join NCT03698149 on ClinicalTrials.gov

3. Care in Multiple Sclerosis (MS)

   This study is structured around three main aims. In Aim 1, investigators will conduct community-based participatory research (CBPR) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (MS). Aim 2 will investigate the impact of childhood adversity on MS outcome…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   6 in total

   Run by

   NYU Langone Health

   See if you can join NCT07011914 on ClinicalTrials.gov

4. Non-invasive BCI-controlled Assistive Devices

   Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   The University of Texas at Austin, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT05183152 on ClinicalTrials.gov

5. Smoldering Inflammation in MS

   The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal in…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Barnes Jewish Center for Clinical Imaging Research, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06591429 on ClinicalTrials.gov

6. Skeletal Muscle Aging and Responsiveness in Aged People With MS

   The purposes of this study are to: 1) compare baseline muscle and cardiovascular health in older individuals (>60 years old) diagnosed with MS to age-matched people without MS, 2) determine muscle and whole body changes to an exercise training program, 3) determine if the muscle in a more affected …

   Stage

   Not phased

   Ages

   60 and older

   Site

   Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

   Run by

   Oklahoma Medical Research Foundation

   See if you can join NCT07500727 on ClinicalTrials.gov

7. Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

   Neurogenic overactive bladder (NOAB), characterized by urinary frequency, urgency or urgency incontinence symptoms occurring during the storage phase of the bladder, is the most common urinary complaint in multiple sclerosis (MS). Current management options for NOAB in MS have limited efficacy and …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Houston Methodist Hospital, Houston, Texas

   Run by

   The Methodist Hospital Research Institute

   See if you can join NCT06072703 on ClinicalTrials.gov

8. Intermittent Hypoxia in Persons With Multiple Sclerosis

   This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are sim…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Shirley Ryan AbilityLab, Chicago, Illinois

   Run by

   Shirley Ryan AbilityLab

   See if you can join NCT06276634 on ClinicalTrials.gov

9. Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

   The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive f…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   2 in total

   Run by

   Tr1X, Inc.

   See if you can join NCT07477639 on ClinicalTrials.gov

10. People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

    The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of int…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT07207148 on ClinicalTrials.gov

11. Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of ~12 months. 2. study the…

    Stage

    Phase 4

    Ages

    18 to 70

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT07225361 on ClinicalTrials.gov

12. Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

    This randomized controlled factorial trial will examine whether and how relaxation training, behavioral activation, and cognitive therapy improve fatigue and functioning in fatigued adults living with multiple sclerosis.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Multiple Sclerosis Center at UW Medical Center - Northwest, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT06809192 on ClinicalTrials.gov

13. A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

    A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Stanford Multiple Sclerosis Center, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06138132 on ClinicalTrials.gov

14. Blood Flow Restriction And Veterans With MS

    There currently is a lack of evidence to support exercise interventions in people with advanced disability due to MS (i.e., need assistance to walk or use a wheelchair). This project proposes to study a strength training program using blood flow restriction (BFR) in people with advanced disability …

    Stage

    Not phased

    Ages

    18 to 75

    Site

    Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado

    Run by

    VA Office of Research and Development

    See if you can join NCT05433103 on ClinicalTrials.gov

15. Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

    This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found…

    Stage

    Not phased

    Ages

    18 to 75

    Site

    Shirley Ryan AbilityLab, Chicago, Illinois

    Run by

    Shirley Ryan AbilityLab

    See if you can join NCT06390930 on ClinicalTrials.gov

16. Central Vein Sign in Multiple Sclerosis Extension Study

    Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and …

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Cleveland Clinic Foundation, Cleveland, Ohio

    Locations

    3 in total

    Run by

    The Cleveland Clinic

    See if you can join NCT07424027 on ClinicalTrials.gov

17. Multiple Sclerosis Implementation Network (Registry)

    The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals C…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Multiple Sclerosis Association of America, Cherry Hill, New Jersey

    Locations

    3 in total

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT07415824 on ClinicalTrials.gov

18. A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

    The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product)…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Colorado, Denver, Denver, Colorado

    Run by

    Kyverna Therapeutics

    See if you can join NCT07403188 on ClinicalTrials.gov

19. Retinal Imaging in Neurodegenerative Disease

    This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke University Medical Center, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT03233646 on ClinicalTrials.gov

20. Molecular Imaging of NET Using [C-11]MRB-PET in MS

    This study aims to use [C-11]MRB PET (positron emission tomography) imaging to look at brain injury in patients with Multiple Sclerosis (MS) and healthy individuals. The overarching hypothesis is that there is decreased radioligand binding to the norepinephrine transporter in multiple sclerosis, re…

    Stage

    Phase 1

    Ages

    18 to 60

    Site

    Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT03207464 on ClinicalTrials.gov

21. PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

    The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary …

    Stage

    Phase 1

    Ages

    18 to 85

    Site

    Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT02649985 on ClinicalTrials.gov

22. Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

    The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years…

    Stage

    Not phased

    Ages

    2 and older

    Site

    Brain Inflammation Collaborative, Delafield, Wisconsin

    Run by

    Brain Inflammation Collaborative

    See if you can join NCT04806620 on ClinicalTrials.gov

23. Home Based Functional Balance Intervention for Multiple Sclerosis

    The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Spe…

    Stage

    Not phased

    Ages

    40 to 90

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT07355387 on ClinicalTrials.gov

24. Assessment of Synaptic Density in MS

    The investigators propose to use the novel SV2a-PET ligand, [F-18]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and po…

    Stage

    EARLY_Phase 1

    Ages

    18 to 60

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04634994 on ClinicalTrials.gov

25. Glucose Consumption in MS Using [F-18]FDG-PET

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of [F-18]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting…

    Stage

    Phase 4

    Ages

    18 to 70

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT07087106 on ClinicalTrials.gov